Attovia Therapeutics (ATTO) Stock Forecast: StockMap's 2-Week Call

ATTO stock forecast: StockMap's model leans Underperform on Attovia Therapeutics for the two weeks after the Nov 16 close, toward ATTO trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 3 of 5 two-week windows on ATTO since Aug 26; by chance, a call on the same dates was right 62% of the time.

Attovia Therapeutics last closed at $14.72, -2.71% on the session.

Against the IVW growth benchmark the position is -0.09% over the forecast window.

Attovia Therapeutics' market cap is $672.89M as of November 16, 2026.

Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -42 (too close to call).

Where ATTO sits: sized by market cap, coloured by the day's move.

The read is built from 11 underlying insights — 1 bullish and 10 bearish.

Agreement across those insights is 91%.

40 daily calls for ATTO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Attovia Therapeutics in the 0th percentile on return on equity, where 100 is best.

Attovia Therapeutics is classified under Health Care / Biotechnology.

StockMap tracks Attovia Therapeutics as the 150th largest of the 392 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 191 Moderate Underperform, 151 Neutral, 36 Strong Underperform and 14 Moderate Outperform.

On that composite Attovia Therapeutics ranks 303rd of 392 in the group, against a group median of -0.27.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 16, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Attovia Therapeutics (ATTO) — StockMap 2-week forecast & tracked accuracy